A5032719586- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- BRCA gene mutations in cancer
- Genetic factors in colorectal cancer
- Colorectal Cancer Treatments and Studies
- Radiomics and Machine Learning in Medical Imaging
- Colorectal Cancer Screening and Detection
- Head and Neck Cancer Studies
- Lung Cancer Diagnosis and Treatment
- Advances in Oncology and Radiotherapy
- Health and Medical Research Impacts
- Protein Degradation and Inhibitors
- Prostate Cancer Treatment and Research
- Cancer-related Molecular Pathways
- CAR-T cell therapy research
- Clinical practice guidelines implementation
- Ethics in Clinical Research
- Multiple Myeloma Research and Treatments
- Gastric Cancer Management and Outcomes
- Lymphoma Diagnosis and Treatment
- Prostate Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
Durham VA Medical Center
2019-2024
Duke Medical Center
2019-2021
Duke University
2020-2021
Duke University Health System
2019-2021
Duke Cancer Institute
2020
University of Michigan
2017
University of North Carolina at Chapel Hill
2014
PURPOSE: Next-generation sequencing (NGS) gene panels are frequently completed for patients with advanced non–small-cell lung cancer (NSCLC). Patients highly actionable variants have improved outcomes and reduced toxicities the use of corresponding targeted agents. We sought to identify barriers agent within Veterans Health Affairs' National Precision Oncology Program (NPOP). METHODS: A retrospective evaluation NSCLC who underwent NGS multigene through NPOP between July 2015 February 2019...
// Carlos Murga-Zamalloa 1, 2 , Avery Polk 1 Walter Hanel Pinki Chowdhury Noah Brown Alexandra C. Hristov Nathanael G. Bailey 3 Tianjiao Wang Tycel Phillips Sumana Devata Pradeep Poonnen Juan Gomez-Gelvez 4 Kedar V. Inamdar and Ryan A. Wilcox Department of Internal Medicine, Division Hematology Oncology, University Michigan, Ann Arbor, MI, USA Pathology, Hematopathology, Pittsburgh, PA, Henry Ford Hospital, Detroit, Correspondence to: Wilcox, email: rywilcox@med.umich.edu Keywords: PLK-1;...
The Veterans Health Administration (VHA) is the largest cancer care provider in United States, with added challenge of serving more than twice percentage patients rural areas national average. VHA established National Precision Oncology Program 2016 to implement and standardize practice precision oncology across diverse system.Tumor or peripheral blood specimens from veterans advanced solid tumors who were eligible for treatment submitted next-generation sequencing (NGS) at two commercial...
3074 Background: Scalable next generation sequencing (NGS) technologies have enabled incorporation of precision oncology into clinical practice, informing treatment decisions based on tumor genomics. The Veterans Health Administration (VHA) is the largest integrated healthcare system in U.S., serving a higher percentage rural patients (36%) than national average (14%). To implement and standardize practice across diverse system, VHA established National Precision Oncology Program (NPOP)....
Background To support the rising need for testing and to standardize tumor DNA sequencing practices within U.S. Department of Veterans Affairs (VA)'s Health Administration (VHA), National Precision Oncology Program (NPOP) was launched in 2016. We sought assess oncologists' practices, concerns, perceptions regarding Next-Generation Sequencing (NGS) NPOP. Materials methods Using a purposive total sampling approach, oncologists who had previously ordered NGS at least one sample through NPOP...
Background Colorectal cancer (CRC) risk is partly conferred by common, low-penetrance single nucleotide polymorphisms (SNPs). We hypothesized that these SNPs are associated with outcomes in metastatic CRC. Methods Six candidate from 8q24, 10p14, 15q13, 18q21 were investigated for their association response rate (RR), time to progression (TTP) and overall survival (OS) among 524 patients treated on a phase III clinical trial of first-line chemotherapy Results rs10795668 was weakly TTP (p =...
The Veterans Health Administration (VHA) is the largest integrated health care system in United States (US). Among VHA patients, rate of use concurrent chemoradiation therapy (CCRT) among those with unresectable, stage III non-small cell lung cancer (NSCLC) unknown. objective was to report recent CCRT treatment patterns patients and identify characteristics associated receipt CCRT.Using Department Veteran Affairs (VA) Cancer Registry System data linked VA electronic medical records, we...
7075 Background: Tumor profiling identifies patients who are eligible for targeted anticancer therapies. Common tumor approaches include gene panel testing (TGPT), which tests common mutations in select genes, and multigene sequencing (MGPS), a broad range of comprehensive set genes. Our objective was to determine the lifetime cost-effectiveness MGPS TGPT compared no Veterans with metastatic lung adenocarcinoma from Health Administration’s (VHA) perspective. Methods: A decision analytic...
2005 Background: Next-Generation Sequencing (NGS) gene panels are often completed to guide therapeutic decisions for patients with advanced stage non-small cell lung cancer (NSCLC). Patients highly-actionable variants may experience improved treatments and reduced toxicities use of targeted agents. Ensuring appropriate prescription therapies is therefore high importance. We sought identify barriers agent within the Veterans Health Affairs’ (VHA) National Precision Oncology Program (NPOP)....
Background: Genomic sequencing of tumor samples is often considered for patients diagnosed with metastatic malignancies. In July 2016, the Veterans Health Administration (VHA) created VA National Precision Oncology Program (NPOP) to offer next generation (NGS) multigene panels veterans advanced solid tumors. We sought assess perceptions NPOP among medical oncologists across VHA. Methods: Semi-structured interviews were designed evaluate following concepts: expectations NGS testing, required...